Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors
The trial investigates the combination of CT-011, an anti-PD-1 monoclonal antibody, with a p53 vaccine in patients with advanced solid tumors that have not responded to standard therapies. This combination aims to enhance immune recognition and destruction of cancer cells with p53 mutations. Given the increasing focus on immuno-oncology, successful outcomes could position this therapy favorably in a competitive market, particularly against existing PD-1/PD-L1 inhibitors. However, the trial's withdrawal status raises concerns regarding the feasibility and potential market entry of this combination therapy. Further diligence is required to assess the implications of this withdrawal on ongoing and future development efforts.
Indication: Breast Cancer
Modality: protein therapy
Target: PD-1 receptor inhibition and p53 protein overexpression
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-1 receptor inhibition and p53 protein overexpression
View original source fields
Condition raw: Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Condition normalized: Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: PD-1 receptor inhibition and p53 protein overexpression
Target normalized: PD-1 receptor inhibition and p53 protein overexpression